scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1037114827 |
P356 | DOI | 10.1038/CMI.2012.5 |
P932 | PMC publication ID | 4012849 |
P698 | PubMed publication ID | 22543833 |
P5875 | ResearchGate publication ID | 224867570 |
P2093 | author name string | David L Caudell | |
Christopher M Reilly | |||
Cristen B Chafin | |||
Nicole L Regna | |||
Sarah E Hammond | |||
Samuel K Shimp | |||
Marissanichole Rylander | |||
Molly A Read | |||
P2860 | cites work | Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets | Q83853686 |
Amelioration of systemic lupus erythematosus by Withangulatin A in MRL/lpr mice | Q83968963 | ||
Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4 | Q84449235 | ||
Heat shock protein 90 as an endogenous protein enhancer of inducible nitric-oxide synthase | Q24307745 | ||
Dicer insufficiency and microRNA-155 overexpression in lupus regulatory T cells: an apparent paradox in the setting of an inflammatory milieu | Q24625814 | ||
The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity | Q24805385 | ||
EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity | Q27666178 | ||
Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain | Q28216259 | ||
Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation | Q28289317 | ||
Identification of gp96 as a novel target for treatment of autoimmune disease in mice | Q28473392 | ||
Hsp70 inhibits lipopolysaccharide-induced NF-kappaB activation by interacting with TRAF6 and inhibiting its ubiquitination | Q28505337 | ||
HSP90 and the chaperoning of cancer | Q29617504 | ||
Regulation of the Src family kinase Lck by Hsp90 and ubiquitination | Q30164012 | ||
Hsp90 binds CpG oligonucleotides directly: implications for hsp90 as a missing link in CpG signaling and recognition | Q31137510 | ||
Prostaglandin J(2) inhibition of mesangial cell iNOS expression | Q32124072 | ||
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors | Q33388351 | ||
Elevation of the 90 kDa heat-shock protein in specific subsets of systemic lupus erythematosus. | Q33492860 | ||
Differential heat shock protein overexpression and its clinical relevance in systemic lupus erythematosus | Q33565506 | ||
17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells | Q33688498 | ||
The central and multiple roles of B cells in lupus pathogenesis | Q33713303 | ||
Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects | Q33751565 | ||
T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells | Q33842929 | ||
17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition | Q33997214 | ||
B cells as therapeutic targets in SLE. | Q37603296 | ||
B and T cell antigen receptor repertoires in lupus/arthritis murine models | Q38760990 | ||
HSP90 inhibition by 17-DMAG reduces inflammation in J774 macrophages through suppression of Akt and nuclear factor-κB pathways | Q39397699 | ||
17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines | Q40011969 | ||
The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation | Q40085734 | ||
Geldanamycin, an inhibitor of Hsp90, potentiates cytochrome P4502E1-mediated toxicity in HepG2 cells | Q40309277 | ||
The role of hsp90 in SLE. | Q40441562 | ||
In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative | Q40442466 | ||
The atheroprotective properties of Hsp70: a role for Hsp70-endothelial interactions? | Q40452360 | ||
A central role for the Hsp90.Cdc37 molecular chaperone module in interleukin-1 receptor-associated-kinase-dependent signaling by toll-like receptors. | Q40472339 | ||
Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation. | Q40568050 | ||
Enhanced susceptibility to end-organ disease in the lupus-facilitating NZW mouse strain | Q40595107 | ||
Geldanamycin inhibits the production of inflammatory cytokines in activated macrophages by reducing the stability and translation of cytokine transcripts | Q40672465 | ||
Lupus in the Fas lane? | Q41071062 | ||
B cells and autoantibodies in the pathogenesis of lupus nephritis | Q41710759 | ||
Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. | Q42649187 | ||
Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats | Q42670484 | ||
Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis | Q42805871 | ||
Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis | Q43162731 | ||
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid | Q44904799 | ||
Mechanisms and genetics of autoimmunity | Q46133590 | ||
Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. | Q46503835 | ||
Microarray analysis of glomerular gene expression in murine lupus nephritis | Q46813534 | ||
Strain distribution pattern of susceptibility to immune-mediated nephritis | Q47810078 | ||
IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice | Q47901598 | ||
Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. | Q52529090 | ||
IFNgamma induces functional chemokine receptor expression in human mesangial cells | Q61907301 | ||
Increased levels of antibodies to heat shock proteins with increasing age in Mrl/Mp-lpr/lpr mice | Q72048807 | ||
Morphological analysis of autoimmune disease in MRL-lpr,Yaa male mice with rapidly progressive systemic lupus erythematosus | Q72871848 | ||
IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology | Q73149267 | ||
Distinct pathways for NF-kappa B regulation are associated with aberrant macrophage IL-12 production in lupus- and diabetes-prone mouse strains | Q73299746 | ||
Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice | Q73850612 | ||
Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis | Q73925571 | ||
Lupus-specific kidney deposits of HSP90 are associated with altered IgG idiotypic interactions of anti-HSP90 autoantibodies | Q74417662 | ||
Genetic dissection of systemic lupus erythematosus pathogenesis: evidence for functional expression of Sle3/5 by non-T cells | Q74817353 | ||
Elevated levels of the 90 kDa heat shock protein (hsp90) in SLE correlate with levels of IL-6 and autoantibodies to hsp90 | Q77435871 | ||
Correlation of serum measures of nitric oxide production with lupus disease activity | Q78108547 | ||
The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis | Q79299817 | ||
IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions | Q79445141 | ||
PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr | Q79974102 | ||
Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell | Q80427928 | ||
Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts | Q80509552 | ||
Revisiting anti-hsp90 antibodies in systemic lupus erythematosus | Q83126612 | ||
Targeted tumor necrosis factor receptor I preligand assembly domain improves skin lesions in MRL/lpr mice | Q34067270 | ||
T cells as therapeutic targets in SLE. | Q34075552 | ||
mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? | Q34107250 | ||
Interleukin 6 promotes murine lupus in NZB/NZW F1 mice | Q34228814 | ||
Folding of Toll-like receptors by the HSP90 paralogue gp96 requires a substrate-specific cochaperone | Q34313809 | ||
Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. | Q34538178 | ||
Hsp90 inhibitors as novel cancer chemotherapeutic agents | Q34583912 | ||
Functional significance of hsp90 complexes with NOS and sGC in endothelial cells | Q34653954 | ||
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent | Q34720809 | ||
Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases | Q34792083 | ||
The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice | Q34813568 | ||
Th17 and natural Treg cell population dynamics in systemic lupus erythematosus | Q34978528 | ||
Update on Hsp90 inhibitors in clinical trial. | Q35009729 | ||
Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells | Q35096555 | ||
Heat shock proteins as emerging therapeutic targets | Q35545091 | ||
Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA. | Q35554410 | ||
Genetic basis of murine lupus. | Q35661227 | ||
Targeting multiple signal transduction pathways through inhibition of Hsp90. | Q35787276 | ||
PI3K/AKT signaling and systemic autoimmunity | Q35980515 | ||
Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis | Q36013740 | ||
Cytokine expression in lupus kidneys | Q36054818 | ||
Mesangial cells of lupus-prone mice are sensitive to chemokine production | Q36392347 | ||
Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells | Q36560125 | ||
Cell stress induced HSP are targets of regulatory T cells: a role for HSP inducing compounds as anti-inflammatory immuno-modulators? | Q36824283 | ||
Heat shock protein 90: the cancer chaperone | Q36834685 | ||
Hsp90: a novel target for the disruption of multiple signaling cascades | Q36989967 | ||
Experimental anti-GBM nephritis as an analytical tool for studying spontaneous lupus nephritis | Q37077366 | ||
Targeting Hsp90: small-molecule inhibitors and their clinical development | Q37222845 | ||
C3a receptor deficiency accelerates the onset of renal injury in the MRL/lpr mouse. | Q37230515 | ||
Hsp70 and cardiac surgery: molecular chaperone and inflammatory regulator with compartmentalized effects | Q37231027 | ||
Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket | Q37320252 | ||
Loci predisposing to autoimmunity in MRL-Fas lpr and C57BL/6-Faslpr mice | Q37378097 | ||
The AKT axis as a therapeutic target in autoimmune diseases | Q37516005 | ||
The busy life of regulatory T cells in systemic lupus erythematosus | Q37601587 | ||
P433 | issue | 3 | |
P921 | main subject | lupus erythematosus | Q188297 |
systemic lupus erythematosus | Q1485 | ||
P304 | page(s) | 255-266 | |
P577 | publication date | 2012-04-30 | |
P1433 | published in | Cellular and Molecular Immunology | Q26842256 |
P1476 | title | Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus | |
P478 | volume | 9 |
Q34923028 | Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoid |
Q28076199 | Anti-Hsp90 therapy in autoimmune and inflammatory diseases: a review of preclinical studies |
Q35952172 | HSP90 inhibitors decrease AID levels and activity in mice and in human cells. |
Q41075749 | Heat shock protein 90 associates with Toll-like receptors 7/9 and mediates self-nucleic acid recognition in SLE. |
Q35437393 | Heat shock protein 90 inhibition by 17-DMAG attenuates abdominal aortic aneurysm formation in mice |
Q38484421 | Heat shock protein 90: a pathophysiological factor and novel treatment target in autoimmune bullous skin diseases |
Q38749429 | Heat shock proteins in the kidney |
Q36488793 | Heat shock proteins: pathogenic role in atherosclerosis and potential therapeutic implications |
Q38998547 | Hsp90 blockade modulates bullous pemphigoid IgG-induced IL-8 production by keratinocytes |
Q39096609 | Hsp90 inhibition ameliorates CD4(+) T cell-mediated acute Graft versus Host disease in mice |
Q28243562 | Hsp90: a chaperone for HIV-1 |
Q58208711 | Immunomodulatory effects of heat shock protein 90 inhibition on humoral immune responses |
Q37068669 | Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease |
Q38619030 | Inhibitory effects of heat shock protein 90 blockade on proinflammatory human Th1 and Th17 cell subpopulations |
Q29347538 | LPS induces pp60c-src-mediated tyrosine phosphorylation of Hsp90 in lung vascular endothelial cells and mouse lung |
Q36317684 | Role of hsp90 in systemic lupus erythematosus and its clinical relevance |
Q36632310 | Single nucleotide polymorphisms of HSP90AA1 gene influence response of SLE patients to glucocorticoids treatment |
Q26744078 | Spatiotemporal Regulation of Hsp90-Ligand Complex Leads to Immune Activation |
Q35606420 | The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus |